Publications by authors named "S E R Halford"
Article Synopsis
- The study investigates how a novel CHK1 inhibitor, SRA737, affects cancer cell lines with different P53 gene statuses, focusing on non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) cell lines.
- CHK1 is activated in response to DNA damage, allowing damaged cells to pause their cycle; inhibiting CHK1 aims to make these cells more susceptible to treatment by preventing this pause.
- Results show that cancer cells with mutated P53 were more sensitive to SRA737, exhibiting increased DNA damage and reduced proliferation compared to wild-type cells, highlighting the importance of P53 status in cancer treatment response.
X-linked retinoschisis (XLRS) is the most common juvenile macular degeneration in males. Unlike most other X-linked retinal dystrophies, carrier heterozygous females are very rarely reported to show clinical features of the disease. Herein, we describe unusual retinal features in a 2-year-old female infant with family history and genetic testing consistent with XLRS.
View Article and Find Full Text PDFDiabetic Retinopathy (DR) is a leading cause of preventable visual impairment in the working age population. Despite the increasing prevalence of DR, there remain gaps in our understanding of its pathophysiology. This is a prospective case-control study comparing the genetic profiles of patients with no DR vs.
View Article and Find Full Text PDFArticle Synopsis
- Modern cancer therapies are targeting specific aspects of cancer for better effectiveness and tolerability, but many still face issues with side effects and overall tolerability.
- The traditional maximum tolerated dose (MTD) model may no longer be suitable, prompting a move towards a more holistic approach for determining optimal dosing in early clinical trials.
- The FDA's Project Optimus and international collaborations through Project Orbis are working on optimizing dose selection and improving patient access to new cancer therapies, emphasizing the need for reform in how early phase oncology trials are conducted.
Article Synopsis
- The study investigates AZD3965, a novel inhibitor of monocarboxylate transporter 1 (MCT1), intended to evaluate its safety and effectiveness in treating advanced cancers in patients with no standard treatment options.
- During the trial's dose escalation, 40 patients were treated, with common side effects including mild fatigue and changes in retinal function; dose-limiting toxicities mainly occurred at higher doses.
- The findings suggest that AZD3965 is generally well-tolerated at effective doses, establishing an optimal dosage of 10 mg twice daily for further testing in cancers with high MCT1 expression.